News
Stay up to date on NKMax America’s company news and announcements.
Press Releases
2021
2020
NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
/in Press Release /by Denise ChuaNKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors.
/in Press Release /by Denise ChuaNKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers
/in Press Release /by Denise ChuaNKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference
/in Press Release /by Denise ChuaNKMax America To Present Data from Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program
/in Press Release /by Denise ChuaNKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting
/in Press Release, Uncategorized /by Denise ChuaNKMax America to Present at the Upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference
/in Press Release /by Denise ChuaNKMax America to Present Corporate Overview at the Cowen & Company 40th Annual Health Care Conference
/in Press Release /by Aurelia Yee2019
NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy
/in Press Release /by Aurelia YeeNKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer
/in Press Release /by Aurelia YeeNKMax America to Present at 2019 Innate Immunity Conference
/0 Comments/in Press Release /by Denise ChuaNKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer
/in Press Release /by Aurelia YeeNKMax Events
Check back soon for upcoming events!
NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
/in Press Release /by Su Lei YeeAffimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01
/in Press Release /by Su Lei YeeNKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting
/in Press Release /by Su Lei YeeNKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO
/in Press Release /by Su Lei YeeNKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
/in Press Release /by Su Lei YeeNKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer
/in Press Release /by Su Lei YeeNKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
/in Press Release /by Su Lei YeeNKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer
/in Press Release /by Su Lei YeeNKMax America Announces Corporate Name Change to NKGen Biotech
/in Press Release /by Su Lei YeeAffimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
/in Press Release /by Su Lei YeeNKMax America Announces Key Leadership Appointment
/in Press Release /by Su Lei Yee